Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
Darolutamide is developed jointly by Bayer and Orion Corporation
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Subscribe To Our Newsletter & Stay Updated
